At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 165 enrolled
Drug / intervention
Romiplostim +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer
In Brief
A Phase 3 clinical trial evaluating Romiplostim and Placebo for Chemotherapy-induced Thrombocytopenia. Completed, enrolled 165 participants across 117 sites in 20 countries.
Detailed Summary
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy-induced Thrombocytopenia
CountriesArgentina, Austria, Brazil, Bulgaria, Canada, Colombia, France, Greece, Hungary, Italy, Mexico, Peru, Poland, Portugal, Romania, Russia, Spain, Turkey (Türkiye), Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartSep 2019
Primary CompletionJan 2024
Study CompletionJan 2025
TodayJul 2026
First PostedDec 5, 2017
Enrollment StartSep 30, 2019
Primary CompletionJan 25, 2024
Study CompletionJan 9, 2025
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 8.6 years ago
Interventions
Romiplostimbiological
This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.
Placeboother
Placebo Comparator